Medicinal uses and main therapeutic areas of Opicapone

Opicapone is a new type of catechol-O-methyltransferase (COMT) inhibitor, specially developed for patients with Parkinson's disease who experience "end-of-dose fluctuations" during levodopa (levodopa)-based treatment. The main purpose of this drug is to prolong the effective action time of levodopa, thereby reducing "on-off fluctuations" and improving the persistence of patient control of motor symptoms. COMT is an enzyme that can break down levodopa. By inhibiting its activity, Opicapone significantly delays the metabolism of levodopa, allowing it to maintain a higher concentration in the body, thereby improving the stability of Parkinson's disease treatment.

Opicapone is mainly used for patients with moderate to advanced Parkinson's disease. When levodopa alone cannot meet the need for round-the-clock symptom control, this type of auxiliary drug is often used in combination. Compared with traditional COMT inhibitors such as entacapone, the advantage of Opicapone is that it is a once-daily long-acting preparation, which not only improves patient compliance but also reduces the incidence of adverse reactions such as gastrointestinal discomfort and urine discoloration. In the guidelines of many European and American countries, opicapone has been recommended as the first choice adjuvant drug to optimize levodopa therapy.

In addition to improving motor symptoms, Opicapone also plays an important role in improving the quality of life of patients with Parkinson's disease. By reducing "off" time, the period between recurring symptoms, patients' ability to perform daily activities and their mental state can be improved. Especially after long-term use of levodopa, patients face fluctuations in drug efficacy or shortened drug efficacy. Opicapone can effectively extend the plateau period of drug efficacy and is a treatment option that provides symptomatic support rather than direct neuroprotection.

At present, Opicapone has been approved for marketing in the European Union, the United States and many Asian countries. As a new option for combined treatment of Parkinson's disease, its safety and efficacy have been verified in clinical practice.

Reference materials:https://www.ongentys.com/